The iShares Biotechnology ETF (IBB) is an exchange-traded fund designed to track the performance of biotechnology companies listed in the United States. The ETF is managed by BlackRock through its iShares platform and trades under the ticker IBB on the Nasdaq.

Classified as a sector equity ETF, the fund provides exposure to companies involved in drug development, genetic research, molecular biology, innovative therapies, and other areas within the life sciences industry.

The ETF follows a passive management approach and seeks to replicate the performance of the NYSE Biotechnology Index, a benchmark composed of biotechnology and biopharmaceutical companies listed in the U.S. market.

Diversification and sector exposure

IBB provides exposure primarily associated with:

• Biotechnology companies.

• Biopharmaceuticals.

• Gene therapies.

• Medical research.

• Drug development.

• Life sciences.

• Healthcare innovation.

• U.S. healthcare markets.

The portfolio includes companies of various sizes, ranging from established pharmaceutical and biotechnology firms to businesses focused on developing next-generation treatments and medical technologies.

The ETF’s performance is closely tied to scientific breakthroughs, clinical-trial outcomes, regulatory approvals, and the pace of innovation across the biotechnology industry.

FDA decisions, changes in healthcare regulation, trends in medical spending, and advances in areas such as precision medicine, immunotherapy, and gene editing may all influence the fund’s behavior.

Structure and costs

IBB shares trade on the secondary market on the Nasdaq during regular trading hours. Share creation and redemption occur through authorized participants, a mechanism intended to help align the ETF’s market price with its net asset value (NAV).

The fund charges a management fee as outlined in its prospectus and does not apply a performance fee. Dividends received from portfolio holdings may be distributed to shareholders according to the fund’s distribution policy.

Because the ETF focuses on a specialized segment of the healthcare industry, it may experience higher volatility than broader market indexes, particularly during periods driven by regulatory developments or major clinical-trial results.

History and evolution of the ETF

The iShares Biotechnology ETF was launched in 2001 during a period of growing investor interest in companies focused on medical innovation and advanced healthcare technologies.

Since inception, the fund has tracked one of the most dynamic areas of the U.S. equity market, reflecting progress in genomics, molecular biotechnology, and the development of breakthrough therapies.

In recent years, the biotechnology sector has gained further prominence through advances in personalized medicine, gene therapies, vaccines, and treatments for complex diseases, trends that continue to shape the companies represented in the ETF’s portfolio.

Additional Information

iShares Biotechnology ETF (United States) is an exchange-traded fund (ETF), with assets under management totaling $10.40 billion.

Over the past 12 months, iShares Biotechnology ETF recorded a return of 43.74%, with its price trading between $139.07 and $216.96 during the same period.

The ETF is traded under the ticker IBB.